XTALPI Holdings Ltd (02228.HK) shares surged 15.91% at the market open on Wednesday, following the announcement of a significant drug development agreement. The Hong Kong-listed artificial intelligence-driven drug discovery company has entered into a definitive agreement with Dovetree, marking a major step forward in its pharmaceutical research and development efforts.

According to the agreement, which was finalized in late June, XTALPI's unit will collaborate with Dovetree to discover and develop both small molecule and antibody drug candidates. This partnership leverages XTALPI's AI-powered drug discovery platform and could potentially accelerate the development of new therapeutic treatments, significantly boosting the company's position in the competitive pharmaceutical industry.

Investors responded positively to the news, particularly after XTALPI disclosed that it had received an initial payment of $51 million as of August 5. This substantial upfront payment not only validates the potential of the partnership but also provides XTALPI with additional capital to fund its ongoing research and development activities. The market's enthusiastic reaction suggests high expectations for the outcomes of this collaboration and its potential to drive future growth for XTALPI.